NCT04947631已完成3 期
A Multi-center, Randomized, Double-blinded, Double-dummy, Parallel Group, 48-week, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 667
- 试验地点
- 1
- 主要终点
- Change in Total International Prostate Symptom Score (IPSS) from baseline to Week 48
研究概览
简要总结
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.
详细描述
This study is conducted to access whether DKF-313 once daily for 48 weeks is superior to dutasteride 0.5 mg once daily and tadalafil 5 mg once daily each in improving BPH-LUTS as measured by changes in IPSS total scores.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 45 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male aged 45 to 80 years
- •BPH diagnosis
- •Voluntarily signed the informed consent form
- •Willing to participate in the study
- •Total IPSS 13 or greater at baseline
- •Prostate volume 30 cc or greater by TRUS at baseline
- •Qmax 4 to 15 mL/s and minimum voided volume 125 mL or greater at baseline
排除标准
- •Serum PSA 4 ng/mL or greater with a positive biopsy result
- •Malignant urogenital tumors including prostate cancer, bladder cancer, etc.
- •Previous prostatic surgery including TURP, balloon dilatation, thermotherapy and stent replacement or other invasive procedures to treat prostate
- •Prostate biopsy within 4 weeks of screening
- •Use of alpha-blockers, alpha-agonists, phosphodiesterase type 5 (PDE5) inhibitors, antidiuretics, anticholinergics, cholinergics, antispasmodics, nitrates or herbal preparations affecting prostate within 4 weeks of screening, or 5-alpha reductase inhibitors (5-ARIs) within 24 weeks of screening
- •Acute urinary retention within 12 weeks of screening
- •Any causes other than BPH resulting in urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, bladder malignancy, acute or chronic prostatitis, acute or chronic urinary tract infections)
- •Bladder postvoid residual 200 mL or greater
- •Anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease) or conditions that might predispose to priapism (such as sickle cell anemia, multiple myeloma, or leukemia)
- •Cardiovascular diseases such as myocardial infarction within 12 weeks of screening, unstable angina or angina during sexual intercourse, heart failure (NYHA Class 2 or higher) within 24 weeks of screening, uncontrolled arrhythmias, hypotension (<90/50 mmHg) or uncontrolled hypertension (>170/100 mmHg), or stroke within 24 weeks of screening
- •Left ventricular outflow obstruction (e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis)
- •Inherited disorders including galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •Inherited retinal degeneration including retinitis pigmentosa
- •Vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION)
- •Hypersensitivity to ingredients of investigational products
- •Alcohol or drug abuse or treating psychiatric disorders
- •Severe hepatic impairment (ALT or AST > 3xULN)
- •Renal impairment with severe heart failure (serum creatinine > 2xULN)
- •Uncontrolled diabetes (HbA1c 9% or greater)
- •Other investigational products or procedures within 12 weeks of screening
- •Plans to have a child or unwilling to comply with using medically accepted contraception methods (such as surgical sterilization and condom) during the treatment period
- •Not eligible due to other reasons at the investigator's discretion
研究组 & 干预措施
DKF-313
Experimental
Dutasteride 0.5mg + Tadalafil 5mg
干预措施: DKF-313 (Drug)
Tadalafil
Active Comparator
Tadalafil 5mg
干预措施: DKF-313 placebo (Drug)
DKF-313
Experimental
Dutasteride 0.5mg + Tadalafil 5mg
干预措施: Dutasteride placebo (Drug)
DKF-313
Experimental
Dutasteride 0.5mg + Tadalafil 5mg
干预措施: Tadalafil placebo (Drug)
Dutasteride
Active Comparator
Dutasteride 0.5mg
干预措施: Dutasteride (Drug)
Dutasteride
Active Comparator
Dutasteride 0.5mg
干预措施: DKF-313 placebo (Drug)
Dutasteride
Active Comparator
Dutasteride 0.5mg
干预措施: Tadalafil placebo (Drug)
Tadalafil
Active Comparator
Tadalafil 5mg
干预措施: Tadalafil (Drug)
Tadalafil
Active Comparator
Tadalafil 5mg
干预措施: Dutasteride placebo (Drug)
结局指标
主要结局
Change in Total International Prostate Symptom Score (IPSS) from baseline to Week 48
时间窗: Weeks 0 and 48
次要结局
- Change in Total International Prostate Symptom Score (IPSS) from baseline to Weeks 4, 12, 24 and 36(Weeks 0, 4, 12, 24 and 36)
- Change in Total International Prostate Symptom Score (IPSS) voiding (obstructive) subscores from baseline to Weeks 4, 12, 24, 36 and 48(Weeks 0, 4, 12, 24, 36 and 48)
- Change in Total International Prostate Symptom Score (IPSS) storage (irritative) subscores from baseline to Weeks 4, 12, 24, 36 and 48(Weeks 0, 4, 12, 24, 36 and 48)
- Change in Total International Prostate Symptom Score (IPSS) Quality of Life (QoL) index from baseline to Weeks 4, 12, 24, 36 and 48(Weeks 0, 4, 12, 24, 36 and 48)
- Change in Qmax from baseline to Weeks 24 and 48(Weeks 0, 24 and 48)
- Change in post void residual (PVR) volume from baseline to Weeks 24 and 48(Weeks 0, 24 and 48)
- Change in prostate specific antigen (PSA) from baseline to Weeks 24 and 48(Weeks 0, 24 and 48)
- Change in prostate volume (PV) from baseline to Week 48(Weeks 0 and 48)
研究者
研究点 (1)
Loading locations...
相似试验
暂停
3 期
Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following BunionectomyPain, PostoperativeNCT05324358Neumentum, Inc.341
已完成
3 期
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPulmonary Disease, Chronic ObstructiveNCT04133909GlaxoSmithKline806
已完成
4 期
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureType 2 Diabetes MellitusHeart FailureNCT02917031AstraZeneca348
已完成
1 期
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy ParticipantsHealthy VolunteerNCT02717754Hoffmann-La Roche99
已完成
2 期
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionSevere Postpartum DepressionNCT02614547Supernus Pharmaceuticals, Inc.21